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ABSTRACT The objective of this document was to standardise published cardiopulmonary exercise
testing (CPET) protocols for improved interpretation in clinical settings and multicentre research projects.
This document: 1) summarises the protocols and procedures used in published studies focusing on
incremental CPET in chronic lung conditions; 2) presents standard incremental protocols for CPET on a
stationary cycle ergometer and a treadmill; and 3) provides patients’ perspectives on CPET obtained
through an online survey supported by the European Lung Foundation. We systematically reviewed
published studies obtained from EMBASE, Medline, Scopus, Web of Science and the Cochrane Library
from inception to January 2017. Of 7914 identified studies, 595 studies with 26523 subjects were included.
The literature supports a test protocol with a resting phase lasting at least 3 min, a 3-min unloaded phase,
and an 8- to 12-min incremental phase with work rate increased linearly at least every minute, followed by
a recovery phase of at least 2–3 min. Patients responding to the survey (n=295) perceived CPET as highly
beneficial for their diagnostic assessment and informed the Task Force consensus. Future research should
focus on the individualised estimation of optimal work rate increments across different lung diseases, and
the collection of robust normative data.
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Introduction
Cardiopulmonary exercise testing (CPET) is useful in the assessment of subjects with chronic lung
conditions as it may help to: 1) recognise physiological factors limiting exercise (with or without the
presence of psychogenic limiting factors); 2) identify these factors as potential therapeutic targets; 3) allow
quantification of the level of impairment; 4) assess the effects of an intervention; and 5) provide prognostic
information [1–7]. Furthermore, CPET is a common procedure in research. To enable comparison of
CPET results to normative data, to compare patient groups and to evaluate the effects of interventions, a
strict standardisation of the CPET procedures is required.
There are several statements by the European Respiratory Society (ERS) [8–10], the American Thoracic
Society and the American College of Chest Physicians (ATS/ACCP) [11] on exercise testing in respiratory
diseases. However, these statements have not focused on the standardisation of CPET, but rather on the
value of exercise testing and technical and physiological considerations. In addition, a North American
initiative with European input has addressed the harmonisation of terminology in exercise medicine (www.
hl7.org/special/Committees/projman/searchableProjectIndex.cfm?action=edit&ProjectNumber=1246) but
has not included standardisation of testing protocols. Thus, the members of this Task Force identified an
important missing gap in the current literature concerning CPET: an evidence-based standard on the
technical performance of CPET as applied to patients with chronic lung diseases.
Therefore, the overall objective of this ERS Task Force was to standardise CPET procedures for people
using CPET as part of clinical and/or research-related investigations (e.g. assessment of the mechanisms/
origin of exercise limitation, evaluation of training programmes and preoperative risk stratification). Thus,
the purpose of the document is to provide a comprehensive account of published CPET procedures that
will be uniformly applied across different settings, such as research. Specifically, based on a systematic
review of the published literature, the Task Force addressed CPET procedures for patients with chronic
lung conditions. The Task Force focused on CPET data with a linear work rate increment, either as a
ramp protocol or with minute-by-minute increments, since such protocols have been recommended for
the assessment of subjects with chronic lung diseases, are widely used in clinical practice [8–10], and are
feasible for the assessment of exercise capacity in children (from the age of 10 years), adolescents, adults
and elderly people with different chronic lung diseases and various degrees of pulmonary impairment. The
Task Force did not include protocols with longer stages, or with an exponentially increasing work rate
since such protocols are not as commonly used and/or do not allow assessment of exercise limitations in
detail. Furthermore, such protocols have their limitations with respect to important outcomes related to
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exercise increments as the anaerobic threshold (AT, determined from breath-by-breath gas exchange
measurements or blood lactate measurements) [12].
The ERS Task Force was formed in October 2016, composed primarily of experts from the ERS
Rehabilitation and Chronic Care Group, the Clinical Respiratory Physiology, Exercise and Functional
Imaging group, the Paediatric Assembly, the Physiotherapists Group, and an ERS methodologist. Task
Force members were clinical scientists and (exercise) physiologists with experience in CPET in a broad
range of paediatric and adult lung diseases. The Task Force received support from the European Lung
Foundation (ELF) throughout the project.
Methodology
First, a short Delphi questionnaire was completed by the Task Force members in November 2016 to set
the search terms and rules for the literature review in January 2017. Data extraction was completed in
November 2017. Between November 2017 and January 2018, a patients’ survey was performed with the
help of the ELF. Thereafter, the manuscript was drafted. Four Task Force meetings were organised in June
2017, September 2017, February 2018 and September 2018. A detailed description of timeline and
processes is available in table S1.
Literature search
Inclusion and exclusion criteria
The literature search focused on studies reporting on CPET (e.g. testing protocols and work rate
increments) in patients with pre-defined lung diseases (table 1). We included studies that used exercise
protocols on a cycle ergometer or treadmill based on minute-by-minute or ramp increments of work rate.
Studies published in European languages and including at least 15 patients per study were considered for
analyses. We excluded studies in which exercise tests were performed: 1) without pulmonary gas exchange
analysis; 2) under hypoxic conditions; 3) in an environmental chamber; and/or 4) on a cycle ergometer in
(semi-) supine position. Review papers, book chapters and conference proceedings were also excluded.
Search methods
EMBASE, Medline (Ovid), PubMed (PreMEDLINE only), Scopus, Web of Science and the Cochrane
Library were searched by an experienced librarian for all articles published from database inception to
12 January 2017. The detailed search strategy for each database can be found in tables S2–S7.
Selection of studies and data extraction
A video conference was held among abstract reviewers to discuss the content and format of the
pre-specified screening spread sheets and to re-evaluate inclusion and exclusion criteria to achieve the best
possible standardisation. Nine Task Force members screened abstracts for inclusion criteria. Each of these
members screened 50 abstracts for training purposes, and the results were compared to those from Task
Force members with experience in conducting systematic reviews (M.A. Puhan, R.A. Rabinovich and
TABLE 1 Exercise mode and protocols used for cardiopulmonary exercise testing
Lung diseases/lung conditions Studies n Cycle test Treadmill test
1-min stages Ramp Unclear 1-min stages Ramp Unclear
COPD/emphysema 323 162 (50.2) 92 (28.5) 36 (11.1) 27 (8.4) 4 (1.2) 2 (0.6)
Asthma 19 7 (36.8) 6 (31.6) 1 (5.3) 5 (26.3) 0 0
Interstitial lung disease 18 5 (27.8) 12 (66.7) 1 (5.6) 0 0 0
Pulmonary arterial hypertension 64 24 (37.5) 37 (57.8) 3 (4.7) 0 0 0
Cystic fibrosis 78 51 (65.4) 22 (28.2) 0 3 (3.8) 2 (2.6) 0
Primary ciliary dyskinesia 1 1 (100) 0 0 0 0 0
Sarcoidosis 12 2 (16.7) 6 (50.0) 4 (33.3 0 0 0
Lung cancer 39 9 (23.1) 21 (53.8) 7 (17.9) 2 (5.1) 0 0
Unclear respiratory diagnosis 3 3 (100) 0 0 0 0 0
Patients undergoing lung transplant or volume
reduction surgery or other thoracic surgeries
23 6 (26.1) 10 (43.5) 4 (17.4) 1 (4.3) 0 2 (8.7)
Other# 15 2 (13.3) 10 (66.7) 2 (13.3) 0 1 (6.7) 0
Total 595 272 (45.7) 216 (36.3) 58 (9.7) 38 (6.4) 7 (1.2) 4 (0.7)
Data are n (%) for each disease/disease condition. No data were available for tuberculosis and irradiation of the lung. #: this group contains a
mix of different lung diseases (i.e. restrictive and obstructive), asbestosis and obstructive sleep apnoea–hypopnea syndrome.
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T. Radtke). Disagreement was discussed among the group to reach consensus. In case of disagreement on
more than five studies, further abstracts were screened and evaluated among Task Force members.
Full-text articles were assessed for studies in which exclusion could not be determined from the abstract.
In a second step, detailed information on study populations, exercise protocols and outcomes was
extracted and entered into a standardised form. Due to the large number of included studies, data
extraction from full-text publications was performed in disease area subgroups. 15 Task Force members
were selected with respect to their research expertise. They received training before and during the data
extraction process to ensure standardised procedures. Finally, two members (T. Radtke and S. Crook)
checked extracted data for consistency and plausibility. If necessary, full texts were re-evaluated and
disagreement was resolved between the members.
Patient survey
In order to gather experiences on CPET from subjects with different lung diseases, the ELF (in
collaboration with the Task Force) conducted an online survey from November 2017 to January 2018. The
survey consisted of a mix of open-ended, closed-ended and Likert scale questions and was available in
nine languages (English, French, German, Greek, Italian, Polish, Portuguese, Russian, Spanish) and was
promoted via the ELF and its affiliated patient organisations and the ERS member network. The English
version of the patient survey can be found in the online supplement.
Agreement reached
Based on the literature review and the patients’ perspectives, Task Force members drafted text passages
that were then circulated among the Task Force members. Issues important for protocol standardisation
and controversial points were discussed during two Task Force meetings. The text was refined until all
Task Force members fully agreed with its content.
All Task Force members declared and signed conflict of interest statements at the beginning of the project
and updated them at project finalisation or when any new relevant conflicts appeared. Conflicts of
interests were managed according to ERS rules.
Results from literature review
Literature search/data extraction
A flow chart of included studies is shown in figure S1. Of 7914 identified studies, 595 studies with 26523
patients were included in the quantitative analysis. Table 1 shows exercise modes and protocols used for
CPET according to respiratory diagnoses and conditions. In tables S8 and S9, study and patient
characteristics are given from studies using either cycle ergometer or treadmill tests. Reported protocol
specifications during CPET and outcomes derived from CPET are given in table 2 and table S10,
respectively. Table S11 shows characterisation of exercise protocol increments for various pulmonary
diagnoses and table 3 specifies criteria used to determine maximal effort during CPET including suggested
estimation equations. In table 4, the Task Force panel suggests outcome values to report in standard
clinical CPET. Whenever the literature review could not inform the Task Force on specific questions, we
referred to existing guidelines or technical standards [8–11].
TABLE 2 Reported protocol specifications during cardiopulmonary exercise testing
Protocol specification Cycle test Treadmill test
n (%)# Median (IQR) n (%)¶ n (%)# Median (IQR) n (%)¶
Work rate increments 487 (89.2) 45 (91.8)
Rest phase 264 (48.4) 10 (20.4)
Rest phase duration min+ 229 (42.0) 3 (3–3) 139 (59) 7 (14.3) 3 (2–3) 4 (57)
Unloaded phase warm-up 329 (60.3) 25 (51.0)
Unloaded duration min+ 314 (57.5) 3 (2–3) 182 (58) 19 (38.8) 3 (3–4) 10 (53)
Incremental phase duration 104 (19.0) 19 (38.8)
Recovery 71 (13.0) 5 (10.2)
Recovery duration min+ 56 (10.3) 3 (2–6) 18 (32) 4 (8.2) 3 (2–4) 1 (25)
Data are presented as n (%) or median (interquartile range). #: studies reporting test protocol details;
¶: studies using test duration supported by the literature review; +: percentages are calculated of studies
that reported on rest, unloaded and recovery phases.
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TABLE 3 Criteria of maximal effort and prediction equations
Variable Cycle test Treadmill test
Children Adults Children Adults
1 V′O2peak Change of V′O2 <2 mL·min
−1·kg−1
for a 5–10% increase in exercise
intensity or of <2SD of the average
increase in V′O2 during the
preceding stages [13]
Change in V′O2 of
<2.1 mL·min−1·kg−1
between consecutive
stages [14]
Change of V′O2
<2 mL·min−1·kg−1 for a
5–10% increase in exercise
intensity or of <2SD of the
average increase in V′O2
during the preceding stages
[13]
Change in V′O2 of
<2.1 mL·min−1·kg−1
between consecutive
stages [14]
2 V′Epeak/MVV % ⩾85 [11] ⩾85 [11] ⩾85 [11] ⩾85 [11]
3 IC Decrease in IC >150 mL during
exercise [15]
Decrease in IC >150 mL
during exercise [15]
Decrease in IC >150 mL
during exercise [15]
Decrease in IC >150 mL
during exercise [15]
4 RER >1.05 [16] >1.05 [17] >1.05 [16] >1.05 [17]
5 HRpeak % pred or
beats·min−1
⩾195 bpm [18] >100% pred [11]
231 men and women
(aged 20–80 years) [19]
Female: 209–0.86×age
Male: 207–0.78×age
⩾200 bpm [18] >100% pred [11]
3320 healthy men and
women (aged 19–89 years)
[17]
211–0.64×age
6 V′O2peak % pred ⩾100% predicted
V′O2peak (L·min
−1) [20]:
Female: V′O2peak=3.08806×height
(m)−2.877
Male: V′O2peak=4.4955×height (m)
−4.640
⩾100% predicted
V′O2peak (L·min
−1) [21]:
V′O2peak=0.046×height
(cm)−0.021×age
−0.62×sex (0 male, 1
female)−4.31
⩾100% predicted
V′O2peak (mL·min
−1·kg−1) [22]:
Female: 58.90–1.15×age
Male: 52.35+0.071×age
V′O2peak (L·min
−1): 3703 male
and 1234 female children and
adolescents (aged
8–16 years) [23]
Male: 0.623+0.230×age
(R2=0.748)
Female: 0.253+0.124×age
(R2=0.529)
⩾100% predicted
V′O2peak (mL·min
−1·kg−1)
[24]:
4637 healthy men and
women (aged 20–90 years)
Female: 17.21
+(0.582×inclination)
+(3.317×velocity)
−(0.116×weight)
−(0.099×age)
Male: 24.24
+(0.599×inclination)
+(3.197×velocity)
−(0.122×weight)
−(0.126×age)
7783 healthy men and
women (aged 20–79 years)
[25]
V′O2 max (mL·min
−1·kg−1):
79.9-(0.39×age)−13.7×sex
[0 male, 1 female])
−(0.127×weight [lbs])
Continued
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TABLE 3 Continued
Variable Cycle test Treadmill test
Children Adults Children Adults
6 Blood lactate Usually not informative, since
there is considerable variability
in post-exercise blood lactate in
children (e.g. max values
between 4–13 mmol·L−1 in
11–13-year old children) [26]
Minimum post-exercise cut-off
values to be validated [27]
Post-exercise blood
lactate levels
⩾8 mmol·L−1 [28, 29]
Usually not informative, since
there is considerable
variability in post-exercise
blood lactate in children (e.g.
max values between
4–13 mmol·L−1 in 11–13-year
old children) [26]
Minimum post-exercise
cut-off values to be validated
[27]
Post-exercise blood
lactate levels
⩾8 mmol·L−1 [28, 29]
V′O2peak: peak oxygen uptake; V′O2: oxygen uptake; V′Epeak: peak minute ventilation; MVV: maximum voluntary ventilation; IC, inspiratory capacity; RER, respiratory exchange ratio; HRpeak,
peak heart rate.
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Exercise testing
Indications/contraindications for exercise testing
CPET is useful in a wide spectrum of clinical practice and a valuable tool in clinical decision making in
lung disease [8, 9, 11, 30]. In general, CPET is used in lung disease for establishing a diagnosis,
determining prognosis, selecting treatment, assessing response to treatment, and follow-up [4]. Indications
for CPET in chronic lung disease include the following. 1) Evaluation of “out-of-proportion” (to resting
functional impairment) exertional dyspnoea and limited exercise tolerance [3]. 2) Preoperative evaluation
(e.g. lung resection surgery, surgical and bronchoscopic lung volume reduction, lung and heart–lung
transplantation) [5]. 3) Indication for and prescription of pulmonary rehabilitation [6]. 4) Functional/
disability, prognostic and response to treatment evaluation in subjects with COPD, pulmonary arterial
hypertension, pulmonary vascular disease, interstitial lung disease or cystic fibrosis (CF) [1, 2, 31–34].
5) Assessment of exercise-induced desaturation and underlying mechanisms [35].
CPET is a relatively safe procedure [36] with a rate of death for patients between two and five per 100000
clinical exercise tests [11]. However, potential risks of CPET have to be weighed against the information
expected from the test. Contraindications include the following [11, 37].
Absolute contraindications: 1) Uncontrolled cardiovascular conditions (acute myocardial infarction, left
main coronary stenosis or its equivalent, unstable angina, moderate or severe stenotic valvular heart
disease, symptomatic uncontrolled arrhythmias including atrial fibrillation with uncontrolled ventricular
rate, severe untreated arterial hypertension, syncope tachyarrhythmias/bradyarrhythmias, active
endocarditis, high-degree atrioventricular block, acute myocarditis or pericarditis, hypertrophic
cardiomyopathy, uncontrolled heart failure, suspected dissecting aneurysm, deep venous thrombosis of
lower limbs). 2) Uncontrolled respiratory conditions (pulmonary embolism, pulmonary oedema, severe
pulmonary arterial hypertension, uncontrolled asthma). 3) Uncontrolled non-cardiorespiratory conditions
affecting or aggravated by exercise (e.g. infection, renal failure, thyrotoxicosis, acute bleeding, electrolyte
abnormalities). 4) Advanced or complicated pregnancy.
Relative contraindications: 1) Resting oxygen saturation (SpO2) ⩽85% on room air (consider the use of
supplemental oxygen). 2) Orthopaedic impairment that compromises exercise performance. 3) Mental or
cognitive impairment leading to inability to cooperate.
Verbal assent to proceed with the test will suffice in most situations, but in some settings, in particular
research, written consent may be required for CPET.
Physiological responses during cycling versus treadmill testing
CPET is typically performed using a cycle ergometer or treadmill, each with its own advantages and
limitations. The literature review identified many more publications on CPET using cycle ergometry
(n=546) than treadmill exercise (n=49) (table 1). Likewise, the number of studied patients is much higher
for cycle ergometer (n=23875) (table S8) than treadmill tests (n=2648) (table S9) covering a wide
spectrum of lung diseases. Although, walking is a familiar activity for most patients and treadmill exercise
TABLE 4 Outcome values to report in standard clinical cardiopulmonary exercise testing as
employed by the Task Force members
Exercise capacity
Cardiovascular
limitation Gas exchange limitation Ventilatory limitation
Variable relevance
V′O2peak HRpeak V′E/V′CO2 slope V′Epeak in % MVVrest
Peak WR V′O2/WR slope Lowest V′E/V′CO2 value (nadir)
AT O2pulsepeak
HR/V′O2 slope
SpO2peak
Borg symptom scores
For studies featuring additional
measurements
VD/VT
# VT/IC
¶
PA–aO2peak
# IRVpeak
¶
V′O2peak: peak oxygen uptake; WR: work rate; AT: anaerobic threshold; HR: heart rate; V′E: minute
ventilation; V′CO2: carbon dioxide production; V′Epeak: peak minute ventilation; MVVrest: maximum voluntary
ventilation at rest; V′O2: oxygen uptake; SpO2peak: peak arterial oxygen saturation measured by pulse
oximetry; VD/VT: dead space/tidal volume ratio; IC: inspiratory capacity; PA–aO2peak: peak alveolar–arterial
oxygen tension difference; IRVpeak: peak inspiratory reserve volume.
#: in studies featuring arterial blood
gas measurements; ¶: in studies featuring serial inspiratory capacity measurements.
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therefore more closely approximates activities of daily living [38] than cycling, the more frequent use of
cycle ergometry is likely related to other advantages of this exercise mode [39]: work rate is easier to
quantify and control; the variability of the intensity of the exercise increments when using a fixed protocol
on cycle ergometer is easier to determine with patients of different body weights; it allows more
convenient intra-test procedures such as blood sampling and blood pressure (BP) monitoring, whilst
patients are less likely to fall. Moreover, a cycle ergometer is generally cheaper and requires less space than
a treadmill.
Cycling and walking clearly elicit different physiological adaptations [40–42]. In this context, information
on direct comparison between cycle and treadmill ergometry is scarce and interpretation complicated due
to different linearity in the pattern of V′O2 response secondary to different work increments applied in
each modality [43]. Despite this shortcoming, it has been documented that treadmill compared to cycle
ergometry results in the following. 1) Higher peak oxygen uptake (V′O2peak) in healthy individuals [44, 45].
This finding is in line with the literature review: in patients with various lung diseases such as COPD,
asthma, CF, lung cancer or patients undergoing lung transplant or volume reduction, V′O2peak achieved
during treadmill was, on average, higher as compared to cycling (tables 1 and 2). In addition, it has been
documented that during cycling there is lower peak lactate concentration whilst AT being identified at
higher V′O2 in patients with COPD [46]. 2) Patients during treadmill exercise can exhibit greater systemic
arterial oxygen desaturation [46–48]. 3) Regression slopes for breathlessness as a function of both V′O2 and
minute ventilation (V′E) are higher [48]. Finally, it seems that breathlessness (rather than leg discomfort)
is the most frequently addressed limiting complaint after incremental walking (shuttle walking) compared
with incremental cycling (81% versus 34%). Conversely, quadriceps fatigue is greater during cycling and is
an infrequent feature of incremental walking [49].
These practical, theoretical and physiological characteristics of each modality should guide the practitioner
in selecting the ergometer, taking into consideration the reason(s) for which the CPET was requested. In
addition, if exercise testing is indicated to provide a prescription for exercise training, it is reasonable to
use the same exercise modality that will be used in the training.
Test protocol
Pre-test procedures
Subjects are usually asked to refrain from eating for at least 2 h before testing [8] and to avoid strenuous
exercise for at least 24 h before CPET. Subjects are advised to avoid caffeine on the day of the test [8] and
smoking for at least 8 h prior to the test [11] due to the deleterious impact of carboxyhaemoglobin on the
oxygen transport capacity. Subjects are asked to wear comfortable clothing and appropriate shoes suitable
for exercise. Upon arrival in the laboratory, subject’s medical history (with a complete recording of all
medications in use), along with physical examination and recording of vital signs (heart rate (HR), BP,
SpO2 and body temperature) is performed to determine any contraindication to exercise testing. In subjects
with diabetes mellitus, it is usually advised to measure blood glucose before exercise to reduce the risk of
hypoglycaemia [50]. In case of severe hypoglycaemia, defined as a blood glucose ⩽2.8 mmol·L−1 or
50 mg·dL−1, or a hyperglycaemic event in the previous 24 h requiring assistance, exercise testing is
contraindicated [50]. Subjects currently taking bronchodilators are asked to administer their usual
bronchodilator treatment at least 10 min prior to CPET [51]. Attention is paid to the temperature in the
exercise laboratory (20–22°C) [52], as cold air may foster bronchospasm in susceptible individuals.
It is important to make clear to the subjects that sensations during the test such as shortness of breath and
a heightened sensation of leg effort are to be expected and their quantification and differentiation will be
important for test interpretation. Subjects are informed that the CPET will be terminated at any time they
choose to stop. However, it is emphasised that data collected throughout the test will be highly valuable if
the participant works to near maximal capacity by the end of the CPET. Subjects are then introduced to a
perceived exertion scale and carefully “anchored” to the extremities of the scale as pertaining to both
“shortness of breath” and “leg effort”. The 0–10 modified Borg scale is the most widely used in clinical
practice wherein “0” means no dyspnoea at all and “10” the worst shortness of breath ever felt [53, 54].
The following is an example of general instructions, used by the Task Force members: “During every stage
of exercise, we are going to ask you about the intensity of your breathlessness and leg discomfort at that
point in time. As you should avoid speaking during the test, you will use a finger of your hand to point
which number between 0 and 10 best reflects the intensity of each of these sensations”. It is good practice for
the technician or physician to say the number out loud to confirm the selected number.
Most commercially available CPET systems now allow measurements of exertional inspiratory capacity (IC)
to track the behaviour of operational lung volumes (especially relevant in obstructive lung diseases) [55].
For the identification of mechanisms of exertional dyspnoea, measurements of IC are necessary to quantify
the magnitude of exercise-induced dynamic hyperinflation. If the measurement of IC is planned during
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the test, it is important to explain the correct execution of the manoeuvre to the individual before the test
with special emphasis on the importance of fully inflating their lungs. An example for general instructions
is given in the online supplement [56].
Spirometry should be performed prior to CPET [57]. If direct measurement of maximal voluntary
ventilation (MVV) is to be performed, this also should be performed prior to CPET testing [57]. Whilst
direct measurement of MVV may be the gold standard, it is highly effort dependent and can be
unpleasant to perform with the participant feeling light-headed or dizzy, and in some subjects
performance of MVV may induce fatigue. Furthermore, patients often hyperinflate during a voluntary
hyperpnoea manoeuvre which can increase their work of breathing relative to the same ventilation during
the exercise test [58, 59]. Finally, after an MVV manoeuvre, in the experience of Task Force members,
15 min are required to recover to baseline with respect to ventilation and gas exchange.
Calibration of the flow sensor and the gas analysers of the metabolic cart are usually performed just prior
to starting the CPET (see below for more information).
Resting phase
A brief resting period before initiation of exercise allows the patient to familiarise with the testing
apparatus (facemask or mouthpiece, ergometer, ECG probes, etc.) and perform baseline measurements of
SpO2, arterial blood sampling (in selected cases only), ECG, BP, V′E and gas exchange variables. Resting
measurements, especially respiratory exchange ratio (RER), can be helpful in identifying patients
hyperventilating before exercise and can be compared with data obtained during maximal effort. The
literature review showed that the duration of a resting phase was only reported in 42.0% and 14.3% for
cycle and treadmill tests, respectively. Of publications selected during the review process, the most
common resting phase duration being reported was 3 min (table 2). This duration is in line with previous
guidelines and statements [8, 11]. Most Task Force members keep the duration of the resting phase up to
3 min to check that the system is working properly or as long as it is required to obtain accurate and
stable resting measurements (e.g. RER <1.0, V′O2 approximately 3.5 mL·kg
−1·min−1) [52]. This is in
agreement with the results from the literature review (table 2). It is possible not to take measurements
during the entire resting phase but only during the final minute or as long as it takes to reach baseline
values. When tests are conducted with oxygen supplementation, a longer resting period may be needed to
allow for equilibration of higher fraction of inspired oxygen (FIO2) in the alveolar space. Patients can be
asked to take a few deep breaths to expedite this process. If the measurement of IC is planned during the
test, at least three reproducible IC manoeuvres are performed during the resting phase [60].
Unloaded phase
An unloaded phase follows the resting phase. This phase is important in assessing baseline V′O2 and
ventilation associated with vertical leg movements and is necessary for the patient to familiarise themselves
with exercise on the treadmill/cycle ergometer and to warm-up adequately. Most commercially available
cycle ergometers cannot provide a true minimum load of 0 W. Preferably, the minimum work rate on the
cycle ergometer does not exceed 10 W during the “unloaded” phase, and this work rate should be stated in
the test report. A three-minute duration for the unloaded phase has previously been recommended [8, 9, 11]
and is in line with the literature review results (table 2). In patients with severe lung disease, the unloaded
phase may be shorter (but not <2 min) in order to perform the incremental exercise phase before inducing
significant amount of fatigue. If a treadmill is used, the lowest speed may be chosen for baseline
measurements, e.g. 1.0–1.6 km.h−1 [11].
Incremental exercise phase
After resting and unloaded phases, the incremental exercise phase starts. An incremental exercise protocol
adapted to the patient’s characteristics is used in order to allow adequate evaluation and follow-up. Ramp
and uniform minute-by-minute incremental protocols are both acceptable and provide similar outcomes,
when total duration of the incremental phase is the same [61, 62]. According to our literature review,
minute-by-minute protocols were used more frequently than ramp protocols for both cycle ergometer (272
versus 216 studies) and treadmill (38 versus 7 studies) exercise testing with 58 (cycle) and 4 (treadmill)
studies not reporting the protocol specifications (table 1). While there was a clear preference for
minute-by-minute cycle ergometer testing protocols in studies on COPD/emphysema and CF, a protocol
preference was less clear for other respiratory conditions. Previous work suggests no differences in
physiological parameters (e.g. maximal HR, V′O2peak and V′Epeak) between minute-by-minute and ramp
exercise testing protocols, in both health and disease [11, 63, 64].
The selected work rate increment allows the duration of the incremental exercise phase to be
approximately 10 min, typically ranging between 8 and 12 min [8]. Choice of the rate of increment
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depends on underlying disease, age, sex, body size, pulmonary function, physical activity, fitness and
possible other factors such as genetics and medication [65–67]. The incremental phase is designed to last
about 10 min, somewhat shorter or longer tests may also provide useful information. However, the work
rate–V′O2 relationship may not be linear in tests lasting <6 min, and may not be useful to assess
submaximal data such as AT [68]. Most importantly, on repeated testing, the same work rate increment is
used. If the measurement of IC is planned during the test, the IC manoeuvres are preferably performed
every 2 min and, if possible, at the end of exercise [60].
Cycle ergometry protocols
Some studies have provided work rate increment estimation for cycle ergometry based on different
variables for patients with COPD [65], CF [66], asbestosis, silicosis and asthma [67]. Other, more general
recommendations for the selection of work rate, increments are based on estimated V′O2peak and V′O2
during unloaded pedalling [8]. An approach to establish work rate increments similar to that of
WASSERMAN et al. [12] was adopted by our Task Force. Table 1 and table S11 provide information on the
work rate increments used and the median peak work rate and V′O2peak measured, as well as the reported
protocol specifications (i.e. median time of each phase, etc.) in the studies included in the literature review
which can contribute to the determination of work rate increments in individual patients. Very few studies
reported test–retest reliability of V′O2peak and peak work rate (table S12).
Based on data available in the literature, we estimated median V′O2peak per kg body weight for the populations
of each pulmonary disease/disease condition (table S13). The patient’s V′O2 at unloaded pedalling (in
mL·min−1) can be estimated from the patient’s body weight according to the equation (150+(6×bodyweight,
kg)) [12]. Assuming an average V′O2 increase of 10 mL·W
−1·min−1 and an assumption regarding the kinetic
delay between increase in exercise intensity and V′O2 response [11], work rate increments (in W), in order to
obtain a ∼10-min incremental exercise phase duration, are calculated as follows:
Cycling work rate increment (Watts per min)=(estimated V′O2peak−estimated V′O2
unloaded (mL·min−1))/92.5
For example, given a patient with CF, 172 cm tall and weighing 60 kg, his estimated V′O2 during unloaded
pedalling is (150+(6×60))=510 mL·min−1. According to table S13 estimated V′O2peak per kg body weight for
this patient should be 34.4 mL·kg−1·min−1, therefore estimated V′O2peak for this patient should be
34.4 mL·kg−1·min−1 × 60 kg=2064 mL·min−1. Hence, for this patient cycling work rate increment can be
calculated as follows:
Cycling work rate increment (per min)=(2064 mL·min−1−510 mL·min−1)/92.5 mL·W−1=16.80 W·min−1
Tables S8 and S9 provide information on weighted median V′O2peak per kg body weight for multiple lung
diseases indicated for cycle ergometer and treadmill testing. Estimated work rate increments have proved
difficult to establish due to the heterogeneity of reported patient data sets (>300) and lung diseases
(table S13). Depending on a subject’s regular physical activity, fitness, reported dyspnoea in daily life (e.g.
Medical Research Council dyspnoea scale) and resting lung function impairment (e.g. forced expiratory
volume in 1 s (FEV1)), work rate increments for an individual test will need to be adjusted. Based on the
current practice of the Task Force members, adjustments of ±5 W·min−1 are usually sufficient.
Nevertheless, validated, easy to use, and disease-specific equations are required and most likely will
improve estimation of work rate increment.
Task Force members would only consider repeating a test with a different work rate increment if data
from the test are insufficient to answer the key clinical or research questions that were posed when
indicating the test.
Treadmill protocols
Various well-established treadmill protocols exist for CPET testing including those of BRUCE et al. [69],
NAGLE et al. [70] and the modified protocol of NAUGHTON et al. [71], during which treadmill speed and/or
slope is increased over time. However, none of these protocols, including their modifications, allows a
linear increase of work rate as a ramp or minute-by-minute increment. However, ramp protocols with
linear increase in work rate have been developed for treadmill testing in healthy adults [43, 60]. PORSZASZ
et al. [43] developed an algorithm using body weight to produce a linear increase in work rate on the
treadmill that more closely mimics the linear increase in metabolic rate seen with cycle ergometry. The
algorithm of PORSZASZ et al. [43] has been adapted to assess patients with diseases such as COPD [47, 72].
For other conditions, treadmill work rate increments have not been published. Due to the low number of
studies using treadmill protocols identified in this review, disease-specific estimation of work rate
increments was felt to be inadequate.
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Recovery phase
After the end of the incremental exercise phase (i.e. after reaching the patient’s limit of tolerance), all Task
Force members employ a recovery period of at least 2–3 min with unloaded pedalling at a reduced cadence
of ∼30 revolutions·min−1 or very slow walking. A prolonged recovery period may be indicated for
individual patients. The recovery phase is useful for safety reasons and may also be of interest for patients
to demonstrate improvements in exercise recovery time after pulmonary rehabilitation and exercise training
programmes. During this period, cardiovascular monitoring (ECG, BP, SpO2, etc.) is typically performed.
Since delayed post-exercise HR recovery is frequently observed in lung disease patients and associated with
dynamic hyperinflation [73] and poor prognosis [74, 75], HR recordings may offer additional useful
information. Furthermore, assessment of perceived exertion, dyspnoea and leg fatigue is done using
standardised scales suggested by BORG et al. [76, 77] and GIFT [78]. Gas exchange measurements can be
terminated and the mask/mouthpiece removed in order to make the patient more comfortable (unless these
measurements are required for specific evaluations during the recovery phase), as was done in patients
suffering from hyperventilation syndrome [79]. In addition, IC manoeuvres may be performed to assess the
rate of recovery of dynamic hyperinflation, but this is mainly done for research purposes.
A flow chart describing the usual practice by Task Force members on the different test protocol phases is
given in figure 1.
V′O2peak verification phase
A supramaximal verification test is a high-intensity, constant load test performed after CPET [80, 81].
Work rate selected for this task is >100% peak power output achieved during CPET. Details on the
methodology of supramaximal verification of V′O2 are provided in the online supplement. Due to paucity
of data in lung disease patients [80–82], the majority of Task Force members abstain from a supramaximal
verification test as part of routine clinical CPET. The test may, however, be useful for research questions
and in cases with suspected invalid peak data during CPET.
Resting phase
3 min (or more if required)
Familiarisation with procedure and equipment:
Recording of resting measurements during the last
minute or longer (until stable baseline is reached)
Unloaded phase
3 min (or less in severely impaired patients)
Unloaded or minimum load
Familiarisation with the ergometer and proper warm-up
Incremental phase
About 10 min (8–12 min)
Ramp or minute-by-minute increment
Standardised increment individually determined for each
patient and disease
Recovery phase
2–3 min
Unloaded pedaling
Safety monitoring
Prolonged recording of heart rhythm and/or gas exchange
during passive recovery, if indicated
FIGURE 1 Flow chart describing the usual practice by Task Force members on different protocol phases and
specifications during cardiopulmonary exercise testing. It is not intended as a recommendation for clinical
practice.
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Technical considerations
Cycle ergometer
Mechanically braked cycling requires maintenance of a specific cycling rate to achieve the specified work
rate [35]. In contrast, performed work rates during electronically braked cycling are directly quantified and
can be computer controlled, leading to work rate being maintained over a wide range of pedalling rates
(40–70 revolutions per minute) [11]. This allows work rate to be incremented automatically and continuously
(e.g. ramp protocol) [11]. According to the American Heart Association (AHA), electronically braked
ergometers have become the standard in clinical testing; but are more expensive and less portable [52]. Cycle
ergometers used in patient testing are medical devices and need to fulfil all respective requirements. A cycle
ergometer needs to be capable of adjusting work rate in increments either automatically or manually [52].
For the most debilitated patients with lung diseases, it is important to use a cycle ergometer that allows very
low (near zero) work rates during unloaded pedalling, so that patients do not have to pedal against flywheel
inertia [11]. In addition, the cycle ergometer must include adjustable handlebars and seat (and crank arms in
smaller children), allowing the knee to be slightly flexed when the pedal is at its lowest position [83]. Meters,
dials or digital displays should be appropriately sized and placed for easy reading [52]. It is advised that
adaptable pedal grips (i.e. to fix the patients’ shoes on the pedal) are employed to optimise performance and
increase patients safety [52]. Regular calibration of the equipment is necessary following the manufacturer’s
specifications. This usually includes measurements of crank arm torque at various speeds using a certified
instrument. If not required more often by local regulations or manufacturer, verification of calibration should
be done annually and after each service/repair of the ergometer [11]. Further information on calibration
procedures and quality control can be found elsewhere [84].
Treadmill
Treadmills for CPET should be electrically driven, are medical devices, and therefore must meet all safety
standards [52]. Optimally, these allow the use of a wide range of individualised incremental and/or ramp
protocols. Specifically, in patients with lung diseases, it is essential that the treadmill offers very slow
walking speed (e.g. 1 km.h−1) and allows inclination of choice. The AHA proposes that a suitable treadmill
should minimally be 127 cm in length and 41 cm in width and should accommodate body weights up to
150 kg [52]. It is advised that a padded front rail and at least one side rail are present to optimise patient
safety, but minimal or (preferably) no handrail support needs to be encouraged as it influences the
metabolic cost of locomotion [68]. An emergency stop button is always visible and directly accessible to
staff and patient. As in cycle ergometry, verification of speed and inclination readings of the treadmill
should be done at least annually [11].
Mouthpiece versus facemask
Subjects can be interfaced to the metabolic cart system via a bite-block mouthpiece, which is combined
with a nose clip and often stabilised by headgear or via a facemask assembly made of pliable rubber that
covers the area of the nose and mouth. Although the mouthpiece/nose clip combination is the gold
standard for measuring respiratory parameters during an incremental exercise test, it can be
uncomfortable for some participants as it makes swallowing difficult, and promotes dry mouth, and/or
throat irritations [85]. In contrast, a facemask assembly provides an alternative to mouthpiece/nose clip
that allows oral and often nasal breathing, as well as swallowing [86]. However, a major concern is that,
with a facemask, it may not be possible to get a tight fit to the face, associated with relevant leakage
particularly at high exercise intensities, thus yielding inaccurate respiratory measurements. Furthermore,
the dead space (VD) is usually larger when using a facemask compared to a mouth piece/nose clip. Past
studies in athletes and lung disease patients have reported lower values of V′O2 (ranging from 5.8% to
24%) during facemask breathing as compared to mouthpiece/nose clip [87–90]. In addition, parameters
such as V′E, tidal volume (VT), carbon dioxide output (V′CO2) and respiratory rate have been reported to
be changed when a facemask was used [85, 86, 89, 90]. Nevertheless, current facemasks are lighter in
weight, have improved contact surface area to prevent leakage, and create a more comfortable fit as
compared to previous models. Indeed, a recent study in healthy individuals did not report any differences
either in gas exchange or breathing patterns between the two different breathing apparatus during both
sub-maximal and maximal levels of exercise [91]. In any case, VD of the system used needs to be fed into
the metabolic cart/analysing software.
From a patient’s perspective, the survey respondents showed no clear preference between mouthpiece/nose
clip and facemask assembly use among 34 (14%) participants who had experience of using both (figures
S2–S4). Of these, 12 participants preferred a mouthpiece, 10 preferred a facemask and 12 had no
preference. Based on the evidence and patient input, both approaches are, therefore, acceptable. Some
additional concerns outlined by respondents who had used both assemblies to those outlined above were
that use of the mouthpiece gave pain in the jaw and palette, a sensation of choking and saliva dripping
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from the mouth can be embarrassing for patients. Additional concerns from using a facemask were that it
gave a feeling of tightness/pressure, panic, fear of suffocation and pain from wearing the mask. It would
seem that use of each assembly is likely to be a personal preference and therefore, where possible, a choice
should be offered to patients following discussion of the advantages and disadvantages of each.
Pulse oximetry
Pulse oximeters rely on the differential transmission of certain light wavelengths by reduced and
oxygenated haemoglobin [92] to estimate arterial oxyhaemoglobin saturation. Pulse oximetry is used to
monitor SpO2 during CPET, which gives a general oxygenation estimate providing a trend during the test
[11, 68]. However, it is reported as an outcome in only around 30% of published studies using CPET as
part of patient assessment (table S10).
A ⩾5% fall in SpO2 during CPET suggests exercise-induced hypoxaemia [11]. In some laboratories, falls of
SpO2 below 85% or 80% constitute an indication to stop the test. Pulse oximeters’ accuracy rates during
exercise are reasonably good (95% CI 4–5%) when compared with direct measurement in arterial blood
oxygenation [93]. Wider confidence limits, however, have been reported, particularly when SpO2 falls below
88% [94] with even further decrease in reliability in populations with dark skin [95, 96]. Most common
inaccuracies in the measurements are due to poor capillary perfusion during exercise (mainly in
cardiovascular diseases) and motion artefacts [97] providing inaccurately lower levels of SpO2. An inaccurate
pulse rate reading from the oximeter can sometimes identify these inaccuracies, but this is not always the
case. Some authors have reported overestimation of SpO2 measured with pulse oximetry [98–100].
Moreover, sensor placement (i.e. finger, earlobe, nose, forehead) may also affect the stability and reliability of
SpO2 recordings. For example, in healthy people and those with cardiovascular disease, forehead sensors have
better precision compared to finger sensors under various testing conditions (i.e. normoxia, hypoxia and
hyperoxia) [101]. Hand motion has been shown to reduce signal quality during finger SpO2 recordings [102]
suggesting use of ear or forehead sensors during cycling or treadmill exercise to be more appropriate. In
patients with digital clubbing, for example in CF, finger sensors underestimate SpO2 readings [103].
Forehead sensors have the advantage that they are less affected by motion and can possibly reduce the
measurement error [101].
It should be recognised that pulse oximeters do not detect methaemoglobin or carboxyhaemoglobin and
will overestimate oxyhaemoglobin saturation in circumstances where these are elevated [104]. In addition,
due to the haemoglobin dissociation curve shape, SpO2 measurements are relatively insensitive to changes
in arterial oxygen tension (PaO2) at levels corresponding to the plateau of the curve [105] (i.e. SpO2 will
remain above 93% and hardly change at PaO2 values >70 mmHg).
Arterial blood gas measurements
The measurement of arterial blood gas requires the placement of an arterial catheter prior to exercise,
preferably into the radial artery [11]. The clinical decision for arterial blood gas measurements during CPET
depends on the purpose of the test; e.g. if pulmonary gas exchange abnormalities are to be expected and
noninvasive estimation of oxygenation is considered inadequate [11]. Blood samples can be taken at rest,
after the unloaded phase, every other minute during the incremental phase and after 2 min of recovery [11].
In general, measurement of PaO2 allows the calculation of gas exchange indices such as the alveolar–arterial
oxygen tension difference. In this case, arterial blood sampling needs to be done using arterialised
capillary blood or from an indwelling arterial catheter at the end of exercise [106]. There is evidence
showing that a puncture performed within 20 s after exercise may capture all episodes of significant
hypoxaemia (i.e. PaO2 <60 mmHg) [107]. Moreover, arterial or arterialised capillary blood gas analyses
have the potential to provide relevant information on arterial carbon dioxide tension, pH, bicarbonate and
lactate levels. The measurement of arterial carbon dioxide tension allows the calculation of VD/VT, a
measure of the efficiency of CO2 exchange. PaO2 levels obtained from capillary blood are less accurate and
should be corrected for the systematic bias between adequately detected disturbances in pulmonary gas
exchanges with a high sensitivity and specificity as previously described [108]. Of note, arterialised earlobe
blood is not a reliable measurement of PaO2 [109].
Heart rate/blood pressure
Electrocardiogram: heart rhythm and ischaemia
Continuous recording of heart rhythm and evaluation of ischaemic changes during exercise and recovery
is crucial for safety and diagnostic reasons. The electrocardiograph should meet the specifications set by
the AHA [110]. The use of two monitors (one for ECG curves) or a wide monitor that is separated into
two screens may facilitate visualisation of ECG curves and detection of arrhythmias during exercise. To
detect arrhythmia and/or ischaemia, continuous oscilloscopic monitoring is recommended [52].
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Additionally, the capacity to deliver a 12-lead printed copy improves interpretation. The Mason–Likar
modification of the 12-lead ECG electrode placement has been widely used in the clinical setting; however,
it may modify the inferior lead complexes [111, 112]. Thus, a standard resting 12-lead ECG is obtained
before CPET [8, 11]. Silver/silver chloride electrodes are recommended for reducing motion artefacts [52].
Skin preparation (i.e. shave area where the electrode is placed) is extremely important regardless of the
type and size of electrodes to achieve high signal quality [52]. Connecting cables between the electrodes
and recorder should be light, flexible and properly shielded to further stabilise the electrocardiographic
signal [52]. Flexible knit “tube” shirts for stabilising the electrodes and cables are widely available [52]. In
the current literature review, peak HR was reported in 49% of the included studies and peak HR expressed
as percentage of predicted normal was reported in 20% (table S10). In fact, peak HR was the fourth most
frequently reported parameter in the included studies. Reporting peak HR in CPET studies is, therefore,
advisable.
Blood pressure monitoring
Manual auscultation is still perceived as the most feasible and accurate method for monitoring BP.
Automated BP devices are widely available and many of them have been designed for use during exercise,
but these devices are expensive and prone to measurement error due to the effects of (chest) motion at high
exercise intensities, especially affecting diastolic BP [113]. If such devices are used, their accuracy should be
validated against manual cuff measurements before routine use during CPET; extreme hyper- or hypotensive
systolic BP readings should be immediately confirmed by manual auscultation [52] or pulse palpation using
the BP system (cuff and pressure readings) which is in place. The exercise test should be terminated if
systolic BP falls >20 mmHg compared to the highest recording during the test and in case of hypertension
(systolic BP >250 mmHg; diastolic BP >120 mmHg) [11]. Cuffs of various sizes, including large and
paediatric should be available [12]. The cuff should be positioned at the level of the heart and the apparatus
should be calibrated [52]. BP is usually monitored every 2 min during CPET. In the current literature review,
peak BP was reported in 10% of the included studies (table S10). While BP is rarely reported in publications,
it is almost unequivocally assessed, according to the experience of the Task Force members.
Metabolic carts
Accurate recording of respiratory volumes and airflow parameters, as well as inspired and expired gases,
requires accurate equipment. With the readily available computers and by utilising specific algorithms, it
has become practical to compute respired flow, volumes and gas concentrations breath-by-breath [114].
Pneumotachographs [115], mass flow sensor transducers [116] and turbines, among other devices, are
widely used in commercially available metabolic carts for sensing volumes and flows at rest and during
laboratory-based exercise testing [117]. These types of transducers must comply with the standards that
have been established by the ATS and ERS for flow and volume measurements [57]. These standards
specify that the devices must have low VD, low resistance to breathing flows and be immune to
temperature changes, and to the water vapor or pools of saliva that may accumulate during exercise [57].
For example, pneumotachographs are sensitive to gas composition variation and temperature changes [118]
as compared to turbine flow meters, that are lightweight and have low VD. However, pneumotachographs
have been considered as more accurate than mass flow sensor transducers [117] With regard to gas
analysers, several systems exist, namely gas collection systems, mixing chamber systems, gas-exchange
measurement at elevated inspired O2 concentrations and more highly developed devices without
employing the Haldane transformation [119]. The advantages and disadvantages of each system have
been previously described in detail [84]. A breath-by-breath system employing a discrete O2 analyser
using paramagnetic or electro-chemical cell technology and a CO2 analyser using non-dispersive infrared
sensor technology or thermal conductivity, as well as mass spectrometry, are suitable for the demands of
CPET [11].
For ensuring valid measurements, the examiner has to follow manufacturer-suggested calibration
procedures for flow and gas analysers. Both flow sensors and gas analysers tend to drift, therefore
calibration procedures immediately preceding each test are recommended. For flow analysers, this includes
calibration using standard volume (typically using a certified 3 L syringe) in at least three flow ranges,
i.e. 2, 4–6 and 8 L·s−1 to assure linearity. Agreement in calculated volumes within ±3% signifies acceptable
performance [84]. The minimum requirements of gas analysers sensors’ performance for measurements
during room-air breathing are: 1) for O2 sensors a detection range between 0–100% and for CO2 sensors a
detection range between 0–10%; 2) sensors’ accuracy of 1%; 3) sensors’ response time of <13 ms; and
4) two calibration points (for each sensor): one in the range of ambient concentration and the other in the
range of exhaled concentration [11, 120]. Preferably, two gases with known gas concentrations should be
used for calibration rather than only one gas and room air [11]. With the help of a metabolic simulator [121]
or testing the same subject (healthy and fit) in at least two or three different submaximal exercise levels
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(physiological calibration) [122] it is possible to regularly perform a global functioning check for assuring
correct ventilatory and gas exchange calculations [84]. The pick-up lead for sampling inspiratory and
expiratory gas needs to be regularly replaced by a new one every 3–6 months. Between tests, it is also
necessary to change the lead to avoid cross infection.
Test with high oxygen concentration
CPET in the condition of hyperoxia (supplemental oxygen) has several applications such as detection of
desaturation during exercise despite oxygen supplementation in patients with intrapulmonary or cardiac
right-to left shunt, and response to supplemental oxygen, particularly in patients with COPD [123–125]
and, although with limited literature support, in CF and interstitial lung diseases [10]. Hyperoxia, however,
can interfere with the performance of the equipment sensors (i.e. oxygen and flow sensors and gas
exchange calculation algorithms). Similarly, at high altitude (hypoxic conditions), reduced humidity and
barometric pressure as well as extreme temperatures can impose a challenge to the equipment.
Supplemental oxygen can alter viscosity of the respired gas (i.e. 11% greater for FIO2=1 in comparison to
FIO2=0.21). In regard to flow sensors, pneumotachographs are more sensitive to changes in air viscosity,
temperature and humidity than turbine volume transducers [11, 126, 127]. In addition, density also
influences Pitot tube flow meters [11] and mass flow meters (that measure mass flow in contrast to flow of
a volume of air) [116]. As for gas concentration sensors, not all of the available methods to measure
concentrations of gases, particularly O2, are accurate in hyperoxic conditions. Paramagnetic oxygen
analysers’ ranges might be limited to FIO2 between 0 and 0.25 [128]. Thus, the technician or physician may
check whether the metabolic cart allows recordings of gas exchange variables when the inspired air
contains a high fraction of oxygen.
Another important issue to consider is the kinetics response of the analysers that can be lengthened by the
increased viscosity of the air in hyperoxic conditions [129].
When intended to use hyperoxic (or hypoxic) conditions, it is mandatory for the equipment to be
adequately validated and calibrated for these conditions. Furthermore, calibration gas mixtures should be
selected to reflect the concentrations of inspired and expired air expected [84].
Infection control considerations
In a busy cardiopulmonary exercise-testing laboratory with a large heterogeneity of patients and disease
entities examined, cross-infection can occur. Therefore, a number of precautions are usually taken and
standards applied.
Cross-infection can occur either via direct contact between patients, indirect contact with contaminated
surfaces, equipment or healthcare personnel, and inhalation of aerosolised particles or droplets via
airborne route, tubing or mouthpieces/facemasks [130]. Direct contact between patients with lung diseases
should be minimised in all cases [131, 132]. Appropriate hand hygiene by healthcare workers should be
applied according to established standards [133] and supervised occasionally in order to improve
compliance. Sufficient time intervals between tests should be used for surface decontamination and room
aeration according to local infection control guidelines [134]. Parts of CPET apparatus that might be
contaminated (e.g. tubing and hand grips) should be disinfected according to manufacturer’s
recommendations [135]. In case of contamination that cannot be dealt with by available means of
disinfection, all contaminated parts are replaced.
In patients known to be infectious, additional precautions may be considered. For example, to prevent
inhalation of microorganisms, barrier filters may be added in case of exercise testing with mouthpieces [136].
However, the additional VD of the filter should be considered in the setup of the metabolic cart. Moreover,
calibration of the flow–volume sensor with the bacterial filter in place is required to accommodate for the
additional resistance. Each patient should be provided with a new or disinfected nose clip. Regardless of
whether CPET is performed with the use of facemask or mouthpiece, after every test facemasks and
multi-use mouthpieces are disinfected according to manufacturer’s and the laboratory standards [135].
Criteria for determining whether a patient reached the limit of exercise tolerance
Once data are verified as being technically acceptable, it is important to consider whether the limit of
exercise tolerance has been reached. In patient populations, this assessment considers subjective (dyspnoea
and leg effort scores, impression of the examiner) and objective criteria (peak HR, RER at peak exercise,
V′E in percent of MVV, and whether or not a plateau in V′O2 was reached near the end of exercise
(attainment of V′O2max)).
It is important to begin data interpretation by reviewing V′O2peak and peak work rate and compare to
reference values that are age, sex and test specific (table 3). A reduced exercise performance may be due
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(solely or in combination) to cardiovascular, ventilatory, gas exchange or musculoskeletal factors, or
simply due to lack of physical conditioning and/or obesity. These need to be separated from reduced
exercise performance that reflects suboptimal effort.
The quantification of V′O2max (typically by using a cycle ergometer or treadmill) requires V′O2 to reach a
value where, despite further increases in work rate, no further (or relatively small) increases in V′O2 occur;
thus a plateau is attained. The plateau required to delineate V′O2max from V′O2peak is often defined by an
increase in V′O2 <2.0 mL·min
−1·kg−1 despite an increase in work rate by 5–10% [13, 17] or, when exercise
intensity is increased minute-by-minute, an increase in V′O2 <150 mL·min
−1 during the last work rate
compared with the immediately preceding one [8].
Importantly, it should be kept in mind that there is no gold standard for defining a maximal effort.
Criteria to delineate a peak effort are as follows (see also table 3) [9, 11]. 1) A plateau in V′O2 is observed.
2) Peak exercise ventilation (V′Epeak) exceeds 85% of directly measured (sprint method) [57] or estimated
MVV [137]. Various methods are used to estimate MVV including: forced expiratory volume in 1 s
(FEV1)×35 [11], FEV1×40 [11, 138], or disease [139, 140] or ethnicity specific equations [141]. Since most
laboratories use the equation FEV1×40 to estimate MVV, this equation seems to be appropriate and is
preferentially used by the majority of Task Force members. 3) Evidence of a ventilatory limitation has
been pointed out by the development of significant expiratory flow limitation (>40%–50% of V′T) and/or
decrease in IC from baseline >150 mL during exercise indicating dynamic lung hyperinflation [10, 15]. 4)
Maximal RER during exercise exceeding 1.05 is considered an indicator of a maximal effort [16, 17]. An
RER >1.05 would be supportive of a maximal test across all ages. 5) The patient reaches a HR at or above
calculated HRmax [11]. 6) V′O2peak exceeds V′O2peak predicted [11]. 7) Peak work rate exceeds peak work rate
predicted [11]. 8) Post-exercise blood lactate levels ⩾8 mmol·L−1 [28, 29].
Subjective scores of dyspnoea, measured for example using the 10-point Borg dyspnoea scale [77] or a 0–100
Visual Analogue Scale (VAS) [142], and the assessment of the supervising technician or physician also add
to the determination of an effort reaching the limit of tolerance. Both the VAS and the Borg Scale have
been shown to provide similar scores during CPET, and to be reliable and reproducible over time in
healthy subjects and patients with cardiorespiratory diseases undergoing CPET [143, 144]. In general,
patients stop exercise at ratings of 5–8 on the modified Borg Scale or 50–80 on the VAS [11, 15, 145]. In
the Task Force working and research experience, ratings indicating severe leg discomfort or dyspnoea on a
Borg scale (7–10 units) or VAS scale (70–100) or a high score on a similar perceived exertion scale are
often used as an indicator for a peak effort.
Figure 2 provides a description of how Task Force members define a maximal test and start to delineate
the reason(s) for exercise limitation in those in whom an abnormal exercise response is noted.
Outcomes to report and variables to consider
The purpose of CPET is to detect exercise intolerance and, if present, define the mechanism(s)
contributing to exercise intolerance. A detailed overview of CPET interpretation in different clinical
scenarios has been recently provided in the 2018 ERS Monograph on Clinical Exercise Testing [13].
Briefly, two variables are used to detect exercise intolerance (table 4). V′O2peak observed during the exercise
test can be compared to normal values [15]. However, V′O2peak has the disadvantage that it is dependent on
motivation as well as physiological capacity [11, 15]. The AT, determined from gas exchange or
measurements of blood lactate, defines the point at which lactate production exceeds lactate elimination
[146, 147]. It has the advantage of being effort independent but relies on pattern recognition for accurate
detection. Gas exchange methods involve determination of the point at which CO2 output accelerates with
respect to O2 uptake, a manifestation of bicarbonate buffering of lactate. The exercise intensity at which
lactate increases, bicarbonate decreases and CO2 output accelerates have been found to be similar,
although modest differences have been detected [148, 149].
Defining cardiovascular limitation to exercise relies on a number of interrelated variables. A low slope or
terminal flattening of the V′O2 over work rate relationship or flattening of oxygen pulse may be diagnostic [3].
Pulmonary vascular causes of cardiovascular limitation may yield a high V′E/V′CO2 slope in addition to
those abnormalities. Low haemoglobin levels will produce oxygen flow deficiency. Primary cardiovascular
limitation may manifest with ECG or BP abnormalities.
Gas exchange limitation to exercise can be CO2-related, O2-related or both. Inefficient CO2 exchange is
manifested by high VD/VT, often signalled by high exercise V′E/V′CO2. A recent publication confirmed the
specificity of high V′E/V′CO2 in defining elevation in VD/VT (as opposed to ventilatory control-mediated
alteration in arterial carbon dioxide tension) [150]. Inadequate oxygen exchange can be detected by
reductions in PaO2 or, less directly, by fall in SpO2 assessed by pulse oximetry [3].
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Ventilatory limitation can be detected by comparing V′Epeak to MVV. Constraints on inspiration can be
detected by comparing exercise V′T trajectory relative to exercise IC. Serial IC manoeuvres may also
be valuable to detect a critical reduction in inspiratory reserve volume [55]. If IC manoeuvres could not be
performed (e.g. in young children), VT/vital capacity may give information on ventilatory limitation [11].
Moreover, evidence of a ventilatory limitation has been pointed out by the development of significant
expiratory flow limitation (>40%–50% of V′T) [151–154].
Determining the V′E/V′CO2 slope provides relevant information especially for patients with pulmonary
hypertension and heart failure [155, 156]. Other relationships such as V′O2/work rate and V′O2 divided by
HR (=oxygen pulse) are also helpful in assessing patients with (suspected) cardiac or vascular disease [30].
Clinical exercise report
A sample summary for a report is provided in the table S14. A clinical exercise report usually consists of
four components.
Basic information on the patient
The report includes name, date of birth, date of test, patient’s characteristics (ECG and pulmonary
function report may be added), and indication(s) for the test.
Technical report
Secondly, there is a technical report, defining protocol and work rate increment used, along with reason(s)
for test termination.
Response to exercise
The report contains the reason for exercise termination, shortness of breath, leg discomfort or both. In addition,
Borg scale scores may be provided at the limit of tolerance. Then, the report describes exercise responses at peak
exercise and, if reliably assessable, also at AT, as well as slopes, namely the following (table S14).
Maximal test?
At least one of:
Plateau in V'O2 (Attainment of V'O2max)
Peak HR >195 (children) or >100% predicted (adults)
V'Epeak ≥85% MVV
RER >1.05
Blood lactate ≥8 mmol·L–1 (adults)
Abnormal exercise response
At least one of:
V'O2peak <85% predicted
Peak HR <90% predicted
V'Epeak >85% MVV
V'O2 at AT <50% predicted V'O2peak
Desaturation ≥5% from baseline
Decrease in IC >150 mL
Early termination
No
Yes
Adverse event
on exercise
e.g. arrhythmia,
pain, etc.
Suboptimal
effort
Yes
Determine cause of exercise limitation
Respiratory
limitation
Reduced
Normal
Reduced
>85%
Normal/reduced
V'O2peak
V'O2 at AT
Peak HR
V'E/MVV
SpO2
Cardiovascular
limitation
Reduced
Normal/reduced
Likely normal
<85%
Normal
Peripheral muscle
limitation
Reduced
Likely reduced
Reduced
<85%
Normal
Peripheral 
deconditioning
Reduced
Reduced
Normal
<85%
Normal
FIGURE 2 Algorithm for determining maximal effort and cause of exercise limitation. This figure describes how the Task Force members
determine the maximal effort and cause of exercise limitation. It is not intended as a recommendation for clinical practice. V′O2: oxygen uptake;
V′O2peak: peak oxygen uptake; V′Epeak: peak minute ventilation; MVV: maximum voluntary ventilation; RER: respiratory exchange ratio; HR: heart
rate; AT: anaerobic threshold; IC: inspiratory capacity; SpO2: arterial oxygen saturation measured by pulse oximetry.
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1) Aerobic/anaerobic response: V′O2peak (% predicted) and peak work rate (% predicted), V′O2 and work
rate at AT, and V′O2/work rate slope.
2) Cardiovascular response: HRmax (% predicted) and V′O2/HR (oxygen pulse) at peak exercise and at AT,
along with BP and ECG responses to exercise.
3) Ventilatory response: V′Epeak and V′Epeak related to MVV. Breathing reserve and/or ventilatory
limitation at maximal exercise is discussed. If available, assessment of dynamic hyperinflation by serial IC
measurements is provided.
4) Gas exchange response: SpO2, as well as ventilatory equivalents (V′E/V′O2, V′E/V′CO2) and end-tidal O2
and CO2 measures at peak exercise. Report V′E/V′CO2 slope. If available, arterial blood gas analysis and
VD/VT (calculated from arterial carbon dioxide tension) are also added.
5) Metabolic response: RER values at rest, AT and peak exercise.
Report summary
Finally, a report summary puts the technical and exercise response information into the context of the
exercising subject; e.g. What does this mean for the patient? What disease processes can be diagnosed?
Data interpretation
The data obtained from a CPET test are not interpreted in isolation. Rather, the interpretation should be
an integration of CPET results with the patient’s history, other clinical findings and investigations. The
results of an exercise test may prompt further technical investigations (e.g. vascular assessment, assessment
of respiratory or peripheral muscle function, etc.). In addition to data directly obtained from the CPET,
feedback from the patient, including reason for exercise termination, can be useful in evaluating exercise
limitation. Figure 2 provides a description of how Task Force members interpret CPET results.
Graphic and tabular representations of CPET variables are fundamental to appreciate the origin of system(s)
limitation. Selection of the most appropriate format for data display is important for discriminating
patterns of abnormality in the exercise response. Suggested forms for tabular and graphic reports of the
results of incremental CPET are discussed in this and other publications [9, 11].
It is important to stress that the graphs chosen display the entire exercise response (rest to peak exercise
and recovery) in addition to the peak values, which are also usually presented in tabular form; this
enhances the interpretation. These submaximal graphic data are revealing and can often be diagnostic. The
use of the appropriate corresponding normal reference values for each plot greatly enhances interpretation
although the available reference data are limited [157]. Interpretation is facilitated if the tabular data are
interval averaged (e.g. 10–15 s), while graphic display is often based on moving averages over four to eight
breaths. For the final report, however, averages over larger intervals (20–60 s) were recommended by the
ATS/ACCP [11]. The appropriateness or inappropriateness of the response of a variable, compared with
the corresponding reference value, is the basis for determining normal or abnormal exercise responses and
mechanism of exercise limitation.
Information to report in exercise-related publications: protocol and outcomes
Our rigorous systematic review identified substantial lack of information in many publications with respect
to the quality of reporting on CPET equipment, testing protocols (table 2) and criteria to determine
maximal effort (table 3). Based on this lack of information and the experience of the Task Force members,
the following information would be useful to be reported in future studies in order to achieve
standardisation of CPET in lung diseases.
Equipment
The type of ergometer (cycle ergometer or treadmill), metabolic cart, equipment used for ECG and SpO2
monitoring and pulmonary gas exchange measurements (mouthpiece or facemask).
The calibration procedures if not standard (e.g. calibration gases for testing with supplemental oxygen).
Exercise protocol and measurements
The CPET protocol including duration of resting, unloaded phase (warm-up), incremental and recovery
periods.
The work rate used during the unloaded phase.
The choice of work rate increments (i.e. ramp or incremental) and how the increment was determined for
individual patients, if different for different patients (i.e. those with severe lung function impairment).
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The actual duration of the incremental phase (mean and standard deviation).
How the criteria were defined for reaching the limit of exercise tolerance and/or a maximal effort and how
many patients actually met these criteria.
Outcomes
The following variables to describe patient characteristics (separately for different disease entities, if
applicable): age, sex, height, weight, body mass index, indices of pulmonary function, V′O2peak, peak work
rate, peak HR, SpO2 at peak exercise, V′E/V′CO2 slope, and V′E/MVV at peak exercise.
Additional CPET outcomes, if relevant, to describe the patient’s or study outcomes.
Report the interpretation of the reason for limited exercise tolerance (i.e. cardiovascular, ventilatory,
muscular and/or detraining).
Results from patient survey
There were 295 respondents from 34 countries; the majority were patients with COPD (26%), sarcoidosis
(18%), CF (16%) or asthma (13%) (figure S5). The most common frequency of CPETs undertaken per
patient per year was two to five (42%), primarily on a cycle ergometer (83%), breathing either through a
facemask (52%), mouthpiece (24%), both on separate occasions (15%) or other gas collection equipment
(9%) (figure S2) without routine use of supplemental O2 during testing (83%). The total duration of CPET
including preparation, resting and recovery period varied, with most being between 20–30 min (46%), and
<20 min (43%); the duration of the test was “mostly acceptable” to 80% of respondents. The preferred
frequency for participating in CPET in the future was once a year (45%) or twice a year (18%) (figure S6).
When asked how much of a problem aspects of CPET were, respondents rated as a “serious problem”:
dryness in mouth (11%), muscle soreness (10%), bicycle seat uncomfortable (9%), coughing (9%) and
mouthpiece uncomfortable (8%). Respondents were asked about the benefits of taking part in CPET with
75% reporting improved knowledge about lung function as the greatest benefit (figure S7). Many patients
perceived the CPET as a highly beneficial part of their routine screening and provided suggestions that
informed this ERS Task Force. For example, suggestions made for improving the test, included: making
the environment quieter, keeping patients warm, having the opportunity to sip water or to use a fan
during the recovery period. They also highlighted the need for more information about the aims and
benefits of the test, a detailed description of the process before taking the test as well as improved
individual care during the test to include greater encouragement for their efforts and clarification for the
reason for stopping the test. Following the test, patients would welcome some dedicated time to discuss the
results with a healthcare professional and for any previous test results to be available for comparison.
Suggestions for further work/research
This Task Force focused on the standardisation of CPET in different pulmonary disease entities,
implementing patient perspectives on CPET and describing a standard protocol for cycle and treadmill
exercise testing. During the work of the Task Force, areas with limited information were identified with
relevance to CPET protocol standardisation as follows.
1) Optimal selection of work rate increments during the incremental phase of the test has only been
addressed in a few studies and lung diseases. Although the Task Force members provided a description of
the available evidence and how to determine the increment for individual patients in this document, more
studies are clearly necessary to validate the suggested approach or to provide a better method.
2) Normative data for CPET are often based on relatively small samples or specific age groups, thereby
limiting their use in clinical practice. Furthermore, selecting norms from different sources hinders the
comparability of CPET results between centres or within registries.
3) Comparison of different CPET procedures within the same patients (e.g. ramp versus minute-by-minute
workload increments, cycle versus treadmill, impact of durations of unloaded pedalling and frequency of
IC manoeuvres) on CPET outcomes.
4) High-quality test–retest reliability studies including patients with different lung diseases and a broad
spectrum of disease severity to provide robust estimates on meaningful changes of CPET outcomes over
time.
Future research, ideally within an ERS Task Force or a clinical collaborative scheme, may focus on the
standardisation of work rate increments for different lung diseases and the collection of large CPET
datasets to establish normal values for relevant CPET outcomes including, but not limited to, V′O2peak in
healthy subjects across a range of ages, sex and ethnicities. The focus of this work should be on cycle
ergometry, since cycle ergometry is used more commonly to assess subjects with lung diseases than
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treadmill, while the data base for normative data is much smaller for cycle ergometry than for treadmill in
healthy adults [24, 25].
Summary
This Task Force statement summarises published protocols to provide an overview of the standard
practices for conducting, reporting and interpreting a CPET. Our findings provide a basis for the
comparison of data from different clinical settings or published studies and identify topics that will be
useful to include data in registries. Furthermore, a standardised protocol allows collection of normative
data. The literature would support a test protocol with a resting phase lasting at least 3 min, a 3-min
unloaded phase (at minimal exercise intensity), and an 8- to 12-min incremental phase with work rate
increased linearly at least every minute, followed by a recovery phase. The interpretation of the test
requires an evaluation of whether the limits of exercise tolerance are reached. Multiple measures obtained
during the test are used to address the questions triggering the test, describe abnormal responses and, if
exercise limitations are detected, identifying causes for exercise limitations. The exercise report ideally
includes key patient’s characteristics and the indication for the test, information on test protocol and
procedures, test outcomes, and a summary of the findings.
There are two areas that specifically require further research: 1) the prediction of work rate increments that
result in an incremental phase of the test lasting about 10 min given the individual differences among
patients in age, sex, body size, lung disease, physical activity, etc.: and 2) the collection of normative data
for all CPET-derived measures that are based on large sample sizes covering the entire age range.
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